Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 4/2008

01-12-2008 | Case Report

Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy

Authors: Shilen Lakhani, Lev Davidson, Dennis A. Priebat, Averell H. Sherker

Published in: Hepatology International | Issue 4/2008

Login to get access

Abstract

Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.
Literature
1.
Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39(3):857–861PubMedCrossRef
2.
Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369(9574):1731–1741PubMedCrossRef
3.
Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95(11):2373–2379PubMedCrossRef
4.
Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103(2):538–544PubMedCrossRef
5.
James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17(5):978–979PubMedCrossRef
6.
Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006;47(1):155–157PubMedCrossRef
Metadata
Title
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy
Authors
Shilen Lakhani
Lev Davidson
Dennis A. Priebat
Averell H. Sherker
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 4/2008
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-008-9099-5

Other articles of this Issue 4/2008

Hepatology International 4/2008 Go to the issue

Review Article

A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B

Case Report

A case of primary small cell carcinoma of the liver that was treated with chemotherapy

Review Article

Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy

Original Article

Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B

Original Article

A 7-day profile of oxidative stress and antioxidant status in patients with acute liver failure

Editorial

Pharmacological effects are model specific in animal models of portal hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits